Glycogen synthase kinase-3 regulates IGFBP-1 gene transcription through the thymine-rich insulin response element

BMC Mol Biol. 2004 Sep 6:5:15. doi: 10.1186/1471-2199-5-15.

Abstract

Background: Hepatic expression of several gene products involved in glucose metabolism, including phosphoenolpyruvate carboxykinase (PEPCK), glucose-6-phosphatase (G6Pase) and insulin-like growth factor binding protein-1 (IGFBP-1), is rapidly and completely inhibited by insulin. This inhibition is mediated through the regulation of a DNA element present in each of these gene promoters, that we call the Thymine-rich Insulin Response Element (TIRE). The insulin signalling pathway that results in the inhibition of these gene promoters requires the activation of phosphatidylinositol 3-kinase (PI 3-kinase). However, the molecules that connect PI 3-kinase to these gene promoters are not yet fully defined. Glycogen Synthase Kinase 3 (GSK-3) is inhibited following activation of PI 3-kinase. We have shown previously that inhibitors of GSK-3 reduce the activity of two TIRE-containing gene promoters (PEPCK and G6Pase), whose products are required for gluconeogenesis.

Results: In this report we demonstrate that in H4IIE-C3 cells, four distinct classes of GSK-3 inhibitor mimic the effect of insulin on a third TIRE-containing gene, IGFBP-1. We identify the TIRE as the minimum requirement for inhibition by these agents, and demonstrate that the target of GSK-3 is unlikely to be the postulated TIRE-binding protein FOXO-1. Importantly, overexpression of GSK-3 in cells reduces the insulin regulation of TIRE activity as well as endogenous IGFBP-1 expression.

Conclusions: These results implicate GSK-3 as an intermediate in the pathway from the insulin receptor to the TIRE. Indeed, this is the first demonstration of an absolute requirement for GSK-3 inhibition in insulin regulation of gene transcription. These data support the potential use of GSK-3 inhibitors in the treatment of insulin resistant states such as Type 2 diabetes mellitus, but suggest that it will be important to identify all TIRE-containing genes to assess potential side effects of these agents.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Benzazepines / pharmacology
  • Cell Line, Tumor
  • Cytoskeletal Proteins / metabolism
  • DNA-Binding Proteins / biosynthesis
  • DNA-Binding Proteins / physiology
  • Forkhead Transcription Factors
  • Gene Expression Regulation / drug effects
  • Glycogen Synthase Kinase 3 / antagonists & inhibitors
  • Glycogen Synthase Kinase 3 / physiology*
  • Insulin / physiology*
  • Insulin-Like Growth Factor Binding Protein 1 / biosynthesis
  • Insulin-Like Growth Factor Binding Protein 1 / genetics*
  • Lithium / pharmacology
  • Nerve Tissue Proteins / biosynthesis
  • Nerve Tissue Proteins / physiology
  • Promoter Regions, Genetic / drug effects
  • Pyridines / pharmacology
  • Pyrimidines / pharmacology
  • Rats
  • Response Elements / physiology*
  • Thymine
  • Trans-Activators / metabolism
  • Transcription, Genetic
  • beta Catenin

Substances

  • Benzazepines
  • Chir 99021
  • Ctnnb1 protein, rat
  • Cytoskeletal Proteins
  • DNA-Binding Proteins
  • Forkhead Transcription Factors
  • Insulin
  • Insulin-Like Growth Factor Binding Protein 1
  • Nerve Tissue Proteins
  • Pyridines
  • Pyrimidines
  • Trans-Activators
  • beta Catenin
  • Foxo1 protein, rat
  • Lithium
  • Glycogen Synthase Kinase 3
  • Thymine